ChartRow logo
EWTX
$39.75+4.83%
as of close, Oct 20, 2026
☾ AH $39.75 +4.83%
PeersMRNALLYMDTUNHJNJTMO
Share this page

Edgewise Therapeutics Inc. trailing returns

How Edgewise Therapeutics Inc. (EWTX) has performed over the last day, week, month and year, over 5 years, and since inception, through October 20, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-20. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day+4.8%+0.0%+4.8%—
5 days+9.6%+0.0%+9.6%-2.6%Oct 16
1 month-12.3%+0.0%-12.3%-19.9%Oct 13
YTD+60.2%+0.0%+60.2%-25.0%Oct 13
1 year+158.3%+0.0%+158.3%-25.0%Oct 2026
5 years+18.3%+0.0%+18.3%+131.2%-75.4%Nov 2023
Since inception (2021)+5.2%+0.0%+5.2%+32.5%-84.7%Nov 2023

Growth of EWTX#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years+18.3%/year · +131.2%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-20). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in EWTX's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is Edgewise Therapeutics Inc.'s return since inception?
Since 2021, Edgewise Therapeutics Inc. (EWTX) has compounded at about +5.2% a year — +32.5% in total.

More on Edgewise Therapeutics Inc.